GLP-1 Market
LLY $1115.70 ▼ -0.7% NVO $43.07 ▼ -2.1% PFE $27.72 ▲ +0.3% VKTX $31.98 ▼ -0.5% KLRA $13.94 ▼ -6.5% GPCR $38.66 ▼ -2.3% RHHBY $52.82 ▼ -0.7%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Evinacumab

Company
Regeneron Pharmaceuticals
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 12, 2026

Find a Clinical Trial Near Me

See recruiting studies for Evinacumab and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07271186

    Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease

    Not yet reported Regeneron Pharmaceuticals 195 participants Est. completion 2028-10-13 58 sites Stand-alone
    Chronic kidney disease
    View official trial listing →
  • Recruiting NCT NCT07447648

    Assessing the Impact of Intensification of Lipid Lowering Therapy With Guidelines-based Evinacumab Administration on Coronary Plaque Volumes Measured by Coronary Computed Tomography Angiography (CCTA) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)

    Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi) 52 participants Est. completion 2029-02 13 sites
    Other conditions: Homozygous Familial Hypercholesterolemia (HoFH), Coronary Computed Tomography Angiography
    View official trial listing →
  • Withdrawn NCT NCT00476983

    Pharmacokinetic and Efficacy of SQV/r 1500/100 Plus Tenofovir/Emtricitabine 300/200 mg

    Not yet reported, Not yet reported The HIV Netherlands Australia Thailand Research Collaboration
    Other conditions: Saquinavir/Ritonavir BID or Lopinavir/Ritonavir BID
    View official trial listing →
  • Completed NCT NCT01749878

    Study to Assess the Safety and Tolerability of Single Doses of REGN1500

    Not yet reported Regeneron Pharmaceuticals 99 participants Est. completion 2016-01 2 sites
    Other conditions: Hypertriglyceridemia
    View official trial listing →
  • Completed NCT NCT02107872

    Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500

    Not yet reported Regeneron Pharmaceuticals 55 participants Est. completion 2015-09 4 sites
    Other conditions: Metabolic Disorders
    View official trial listing →
  • Completed NCT NCT02265952

    Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH)

    Not yet reported Regeneron Pharmaceuticals 9 participants Est. completion 2018-07-23 5 sites
    Other conditions: Homozygous Familial Hypercholesterolemia
    View official trial listing →
  • Completed NCT NCT03146416

    Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers

    Not yet reported Regeneron Pharmaceuticals 96 participants Est. completion 2018-06-14 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT03175367

    Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia

    Not yet reported Regeneron Pharmaceuticals 272 participants Est. completion 2020-12-14 95 sites Stand-alone
    Other conditions: Hypercholesterolemia
    View official trial listing →
  • Completed NCT NCT03399786

    Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

    Not yet reported Regeneron Pharmaceuticals 65 participants Est. completion 2020-03-17 30 sites Stand-alone
    Other conditions: Homozygous Familial Hypercholesterolemia
    View official trial listing →
  • Completed NCT NCT03409744

    Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

    Not yet reported Regeneron Pharmaceuticals 116 participants Est. completion 2023-04-13 38 sites Stand-alone
    Other conditions: Homozygous Familial Hypercholesterolemia
    View official trial listing →
  • Completed NCT NCT03452228

    Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis

    Not yet reported Regeneron Pharmaceuticals 52 participants Est. completion 2020-07-23 17 sites Stand-alone
    Other conditions: Severe Hypertriglyceridemia (sHTG)
    View official trial listing →
  • Completed NCT NCT04233918

    Evaluate the Efficacy and Safety of Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia

    Not yet reported Regeneron Pharmaceuticals 20 participants Est. completion 2023-05-30 11 sites Stand-alone
    Other conditions: Homozygous Familial Hypercholesterolemia
    View official trial listing →
  • Completed NCT NCT04722068

    Regeneron 1331 Kinetics Sub-Study HoFH

    Not yet reported University of Pennsylvania 4 participants Est. completion 2021-01-01 2 sites Stand-alone
    Other conditions: Hypercholesterolemia, Familial
    View official trial listing →
  • Terminated NCT NCT04863014

    Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis

    Not yet reported Regeneron Pharmaceuticals 21 participants Est. completion 2023-02-15 39 sites Stand-alone
    Other conditions: Hypertriglyceridemia
    View official trial listing →
  • Completed NCT NCT05611528

    Safety and Effectiveness of Evinacumab for the Treatment of Homozygous Familial Hypercholesterolemia

    Not yet reported Daniel Gaudet 10 participants Est. completion 2025-03-18 1 site Stand-alone
    Other conditions: Homozygous Familial Hypercholesterolemia
    View official trial listing →
  • Approved For Marketing NCT NCT06500598

    Compassionate Use of Evinacumab

    Regeneron Pharmaceuticals
    Other conditions: Pediatric Homozygous Familial Hypercholesterolemia (HoFH), Severe Hypertriglyceridemia (HTG), Dysbetalipoproteinemia (DBL)
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Evinacumab, Evkeeza®, R1500

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.